In summary, we demonstrate that transcriptome-based co-expression of BRD4 and PD-L1 could be a predictor of poor OS in AML patients, particularly in non-APL patients with intermediate/high risk or under 60 years old (Figure 4C). Here, BRD4 is linked to acute promyelocytic leukemia.